Navigation Links
PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
Date:8/2/2011

MANSFIELD, Mass., Aug. 2, 2011 /PRNewswire/ -- PrimeraDx today announced that Fayyaz Memon has been appointed to the position of Vice President of Regulatory Affairs and Quality Assurance.  

"We are very pleased to have Fayyaz join our team during such an exciting period for the Company," stated President and CEO Matthew McManus.   "Fayyaz comes at a key time, as we've recently launched our first product based on our unique technology for multiplex quantitative PCR, and we will be going to the FDA for clearance later this year.  Fayyaz will bring much needed expertise to take our Quality Systems to the next level and manage our regulatory submissions."

Mr. Memon joins PrimeraDx with over 20 years of experience as an executive in the life sciences and chemical industries.  He has held management positions with Thermo Fisher Scientific, Digene, Johnson&Johnson and SmithKline Beecham and has helped numerous companies to obtain FDA clearances and approvals and to establish quality systems.  He has a unique background covering quality systems, regulatory affairs, FDA remedial actions, software and process validation, manufacturing, and clinical trial services.  Mr. Memon earned his MBA in Operation and Quality Management and MS in Mechanical Engineering from Drexel University.  

"It is a very exciting time to join PrimeraDx!  Not only has the company recently begun commercialization of its core technology, but we are also poised to be a leader in the field of personalized medicine," commented Mr. Memon.  "I believe the product pipeline at PrimeraDx will have a significant impact on patient management, and will help realize the value of genomic medicine."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, 508-618-2300, info@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
2. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
3. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
4. Genstruct Names Louis Latino VP of Sales
5. Codexis Names Vice President, Intellectual Property
6. New England Peptide Names Director of Chemical Development
7. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
8. Board of Directors of Milestone Scientific Names Joseph DAgostino Chief Financial Officer
9. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
10. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
11. BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
Breaking Biology News(10 mins):